Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0 - A Validation Study
Standard
Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0 - A Validation Study. / Topp, Janine; Augustin, Matthias; von Usslar, Kathrin; Gosau, Ramona; Reich, Kristian; Reusch, Michael; Blome, Christine.
in: ACTA DERM-VENEREOL, Jahrgang 99, Nr. 2, 01.02.2019, S. 211-217.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0 - A Validation Study
AU - Topp, Janine
AU - Augustin, Matthias
AU - von Usslar, Kathrin
AU - Gosau, Ramona
AU - Reich, Kristian
AU - Reusch, Michael
AU - Blome, Christine
PY - 2019/2/1
Y1 - 2019/2/1
N2 - This study investigated the validity and feasibility of the Patient Benefit Index 2.0 (PBI 2.0), a short instrument to assess patient-relevant treatment benefit. In a cross-sectional study, patients with skin diseases completed the PBI 2.0 alongside instruments on quality of life and disease-specific PBI long versions to assess convergent validity. Feasibility questions appraise comprehensibility, completeness, length, and readability. Data from a longitudinal study were used to explore responsiveness and test-retest reliability. Most patients rated the PBI 2.0 easy to understand, complete, legible, and not too long. The amount of missing values was overall low. In all groups, except for vitiligo, correlation analyses indicated good convergent validity of PBI 2.0. Responsiveness of the PBI 2.0 could not be clearly confirmed. Retest-reliability achieved satisfactory results. Thus, the PBI 2.0 may be a suitable instrument for its use in different skin diseases. Its broad applicability allows for comparisons across diagnosis groups.
AB - This study investigated the validity and feasibility of the Patient Benefit Index 2.0 (PBI 2.0), a short instrument to assess patient-relevant treatment benefit. In a cross-sectional study, patients with skin diseases completed the PBI 2.0 alongside instruments on quality of life and disease-specific PBI long versions to assess convergent validity. Feasibility questions appraise comprehensibility, completeness, length, and readability. Data from a longitudinal study were used to explore responsiveness and test-retest reliability. Most patients rated the PBI 2.0 easy to understand, complete, legible, and not too long. The amount of missing values was overall low. In all groups, except for vitiligo, correlation analyses indicated good convergent validity of PBI 2.0. Responsiveness of the PBI 2.0 could not be clearly confirmed. Retest-reliability achieved satisfactory results. Thus, the PBI 2.0 may be a suitable instrument for its use in different skin diseases. Its broad applicability allows for comparisons across diagnosis groups.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Chronic Disease
KW - Cross-Sectional Studies
KW - Dermatology/methods
KW - Feasibility Studies
KW - Female
KW - Germany
KW - Health Status
KW - Humans
KW - Longitudinal Studies
KW - Male
KW - Middle Aged
KW - Patient Reported Outcome Measures
KW - Predictive Value of Tests
KW - Quality of Life
KW - Reproducibility of Results
KW - Skin Diseases/diagnosis
KW - Treatment Outcome
KW - Young Adult
U2 - 10.2340/00015555-3063
DO - 10.2340/00015555-3063
M3 - SCORING: Journal article
C2 - 30307024
VL - 99
SP - 211
EP - 217
JO - ACTA DERM-VENEREOL
JF - ACTA DERM-VENEREOL
SN - 0001-5555
IS - 2
ER -
